Adastra Holdings Ltd. operates in the healthcare sector, specializing in cannabis extraction and processing solutions. The company faces significant concerns, including a low financial health score of 11/100, negative EBITDA and net margins, and poor liquidity ratios (current ratio of 0.38 and quick ratio of 0.16), indicating potential solvency issues. While it has a gross margin of 27.5%, the overall financial performance raises red flags, suggesting challenges in profitability and operational efficiency. The market cap of $1.12M also reflects a lack of investor confidence.
Loading financial metrics...
Revenue fell 33.9% year-over-year from $25.5M to $16.9M. The decline has persisted for multiple quarters.
Company posted a loss of $-14.5M over the last year, representing 85.9% of revenue.
Debt of $3.6M is 4.5x the company's cash position of $787K.
Low debt-to-revenue ratio of 21.2% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-Q3 (September 30, 2025)